NeuroPace, the developer of the RNS implantable brain stimulator for the treatment of drug-refractory focal epilepsy, hopes to raise $75m in an initial public offering.
On 24 March, the Silicon Valley company filed an S-1 registration statement with the US Securities and Exchange Commission,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?